News Trial sets up filing for enGene bladder cancer gene therapy enGene is hoping to file its gene for a form of bladder cancer before the end of 2026, based on phase 2 data revealing a 62% complete response rate.
News AHA: MSD's oral PCSK9 matches injectables MSD closes on filing for enlicitide, a PCSK9 inhibitor that could offer the efficacy of injectables with the ease of a once-daily pill.
News Roche's oral MS hope fenebrutinib hits the mark in phase 3 Roche's oral BTK inhibitor fenebrutinib is on track for filings next year for multiple sclerosis after clearing two phase 3 trials.
News AHA: AZ's baxdrostat impresses in resistant hypertension AstraZeneca's data reveal for resistant hypertension treatment baxdrostat suggests its optimism about big sales for the drug could be justified.
News Intellia shares fall after hospitalised CRISPR patient dies Shares in gene-editing specialist Intellia Therapeutics came under renewed pressure today after a patient in one of its clinical trials died.
News Lilly reports 20% weight loss with amylin-targeting drug Eli Lilly has raised the stakes in the obesity market with positive midstage data for its amylin-targeting drug eloralintide.
News FDA follows experts' advice and blocks Capricor DMD therapy The FDA has dashed Capricor's hope of getting approval for its cell therapy for Duchenne muscular dystrophy, wreaking havoc with its share price.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.